These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 15542253)

  • 1. Clinicopathological correlates of aspartyl (asparaginyl) beta-hydroxylase over-expression in cholangiocarcinoma.
    Maeda T; Taguchi K; Aishima S; Shimada M; Hintz D; Larusso N; Gores G; Tsuneyoshi M; Sugimachi K; Wands JR; de la Monte SM
    Cancer Detect Prev; 2004; 28(5):313-8. PubMed ID: 15542253
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic value of humbug gene overexpression in stage II colon cancer.
    Wang J; de la Monte SM; Sabo E; Kethu S; Tavares R; Branda M; Simao L; Wands JR; Resnick MB
    Hum Pathol; 2007 Jan; 38(1):17-25. PubMed ID: 17020779
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased expression of osteopontin is related to tumor aggressiveness and clinical outcome of intrahepatic cholangiocarcinoma.
    Terashi T; Aishima S; Taguchi K; Asayama Y; Sugimachi K; Matsuura S; Shimada M; Maehara S; Maehara Y; Tsuneyoshi M
    Liver Int; 2004 Feb; 24(1):38-45. PubMed ID: 15101999
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The clinicopathologic significance of the expression of vascular endothelial growth factor-C in intrahepatic cholangiocarcinoma.
    Park BK; Paik YH; Park JY; Park KH; Bang S; Park SW; Chung JB; Park YN; Song SY
    Am J Clin Oncol; 2006 Apr; 29(2):138-42. PubMed ID: 16601431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fascin overexpression is involved in carcinogenesis and prognosis of human intrahepatic cholangiocarcinoma: immunohistochemical and molecular analysis.
    Iguchi T; Aishima S; Taketomi A; Nishihara Y; Fujita N; Sanefuji K; Sugimachi K; Yamashita Y; Maehara Y; Tsuneyoshi M
    Hum Pathol; 2009 Feb; 40(2):174-80. PubMed ID: 18835624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Down-regulation of aquaporin-1 in intrahepatic cholangiocarcinoma is related to tumor progression and mucin expression.
    Aishima S; Kuroda Y; Nishihara Y; Taguchi K; Iguchi T; Taketomi A; Maehara Y; Tsuneyoshi M
    Hum Pathol; 2007 Dec; 38(12):1819-25. PubMed ID: 17854859
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinicopathological analysis of colorectal cancer liver metastasis and intrahepatic cholangiocarcinoma: are they just apples and oranges?
    Chiu CT; Chiang JM; Yeh TS; Tseng JH; Chen TC; Jan YY; Chen MF
    Dig Liver Dis; 2008 Sep; 40(9):749-54. PubMed ID: 18329969
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for overall survival in intrahepatic cholangiocarcinoma.
    Schmitz KJ; Lang H; Wohlschlaeger J; Reis H; Sotiropoulos GC; Schmid KW; Baba HA
    Virchows Arch; 2007 Feb; 450(2):135-41. PubMed ID: 17165088
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of p27kip1 protein expression on the biological behavior of intrahepatic cholangiocarcinoma.
    Taguchi K; Aishima S; Asayama Y; Kajiyama K; Kinukawa N; Shimada M; Sugimachi K; Tsuneyoshi M
    Hepatology; 2001 May; 33(5):1118-23. PubMed ID: 11343239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Precancerous bile duct pathology in end-stage primary sclerosing cholangitis, with and without cholangiocarcinoma.
    Lewis JT; Talwalkar JA; Rosen CB; Smyrk TC; Abraham SC
    Am J Surg Pathol; 2010 Jan; 34(1):27-34. PubMed ID: 19898228
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Glycine N-methyltransferase is a favorable prognostic marker for human cholangiocarcinoma.
    Huang YC; Chen M; Shyr YM; Su CH; Chen CK; Li AF; Ho DM; Chen YM
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1384-9. PubMed ID: 18624901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The utility of keratin 903 as a new prognostic marker in mass-forming-type intrahepatic cholangiocarcinoma.
    Aishima S; Asayama Y; Taguchi K; Sugimachi K; Shirabe K; Shimada M; Sugimachi K; Tsuneyoshi M
    Mod Pathol; 2002 Nov; 15(11):1181-90. PubMed ID: 12429797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MUC4 is a novel prognostic factor of intrahepatic cholangiocarcinoma-mass forming type.
    Shibahara H; Tamada S; Higashi M; Goto M; Batra SK; Hollingsworth MA; Imai K; Yonezawa S
    Hepatology; 2004 Jan; 39(1):220-9. PubMed ID: 14752841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aberrant expression of vimentin correlates with dedifferentiation and poor prognosis in patients with intrahepatic cholangiocarcinoma.
    Korita PV; Wakai T; Ajioka Y; Inoue M; Takamura M; Shirai Y; Hatakeyama K
    Anticancer Res; 2010 Jun; 30(6):2279-85. PubMed ID: 20651380
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Up-regulation of fas ligand at early stages and down-regulation of Fas at progressed stages of intrahepatic cholangiocarcinoma reflect evasion from immune surveillance.
    Shimonishi T; Isse K; Shibata F; Aburatani I; Tsuneyama K; Sabit H; Harada K; Miyazaki K; Nakanuma Y
    Hepatology; 2000 Oct; 32(4 Pt 1):761-9. PubMed ID: 11003620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expression of c-erbB-2 and cyclooxygenase-2 in intrahepatic cholangiocarcinoma.
    Choi HJ; Kim HJ; Choi JH
    Hepatogastroenterology; 2009; 56(91-92):606-9. PubMed ID: 19621664
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of MUC1 and MUC2 mucin antigens in intrahepatic bile duct tumors: its relationship with a new morphological classification of cholangiocarcinoma.
    Higashi M; Yonezawa S; Ho JJ; Tanaka S; Irimura T; Kim YS; Sato E
    Hepatology; 1999 Dec; 30(6):1347-55. PubMed ID: 10573510
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma.
    Romani AA; Crafa P; Desenzani S; Graiani G; Lagrasta C; Sianesi M; Soliani P; Borghetti AF
    BMC Cancer; 2007 Dec; 7():232. PubMed ID: 18154639
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Proposal of progression model for intrahepatic cholangiocarcinoma: clinicopathologic differences between hilar type and peripheral type.
    Aishima S; Kuroda Y; Nishihara Y; Iguchi T; Taguchi K; Taketomi A; Maehara Y; Tsuneyoshi M
    Am J Surg Pathol; 2007 Jul; 31(7):1059-67. PubMed ID: 17592273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Altered expression of beta-catenin without genetic mutation in intrahepatic cholangiocarcinoma.
    Sugimachi K; Taguchi K; Aishima S; Tanaka S; Shimada M; Kajiyama K; Sugimachi K; Tsuneyoshi M
    Mod Pathol; 2001 Sep; 14(9):900-5. PubMed ID: 11557787
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.